Disease on EC 3.4.21.7 - plasmin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
Abortion, Spontaneous
Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.
Abscess
Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems.
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Stimulation of plasmin activity in cultured human fibroblast cells by Porphyromonas endodontalis.
The treatment of acute abscesses with human plasmin (fibrinolysin).
Acantholysis
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis.
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Plasmin induces acantholysis in skin organ cultures.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
Acidosis
Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by ph and metals.
Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Atherosclerosis in women with endometriosis.
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis.
Haemocoagulative modifications correlated with pregnancy.
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis.
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis.
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Prothrombotic disorders in children with moyamoya syndrome.
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
[Primary thrombophilia in México. VI: lack of statistical association among the inherited thrombophilic conditions]
[Screening methods in genetic diagnosis of hereditary protein C deficiency]
[Type I protein C deficiency caused by a novel protein C gene mutation]
Acute Coronary Syndrome
Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.
Inflammation, the endothelium, and the acute coronary syndromes.
Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxin-alpha genes and acute coronary syndrome in Czech Caucasians.
Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes.
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Acute Kidney Injury
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
[Fibrinolysin (uroplasmin) therapy of initial manifestations of acute renal insufficiency transfusion]
Acute Lung Injury
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Adenocarcinoma
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Appearance of plasminogen activator activity during a synchronous cycle of a rat adenocarcinoma cell line, PA-III.
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Localization of plasminogen activator(s) in primary and secondary rat adenocarcinoma cells.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activators and inhibitors in ovarian adenocarcinomas.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1.
Proteases in human tumors.
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells.
Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells.
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Adenocarcinoma of Lung
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
Adenocarcinoma, Follicular
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Adenoma
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Role of urokinase in colorectal neoplasia.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
[Blood coagulation disorder in islet cell adenoma]
[Protease activities in gastric and colon cancer tissues]
Adenoma, Islet Cell
[Blood coagulation disorder in islet cell adenoma]
Adenoma, Villous
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
Adenomatous Polyposis Coli
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Adenomatous Polyps
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in human colorectal neoplasia.
Afibrinogenemia
Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Plasminogen interacts with human platelets through two distinct mechanisms.
[Plasmin and congenital afibrinogenemia]
Agammaglobulinemia
Intravenous administration of plasmin treated immunoglobulins in 10 patients with agammaglobulinemia.
Aggressive Periodontitis
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
Periodontitis associated with plasminogen deficiency: a case report.
AIDS-Associated Nephropathy
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Albinism, Ocular
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Albuminuria
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
[Urinary excretion of extracellular matrix proteins in insulin dependent diabetes mellitus]
Alopecia
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Alopecia Areata
The role of plasminogen activators in alopecia areata.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Ligneous periodontitis and Ehlers-Danlos syndrome.
Alzheimer Disease
Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Activators and inhibitors of the plasminogen system in Alzheimer's disease.
Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications.
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.
Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid.
Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.
Association studies between the plasmin genes and late-onset Alzheimer's disease.
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
Plasmin deficiency in Alzheimer's disease brains: causal or casual?
Plasmin system of Alzheimer's disease patients: CSF analysis.
Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
Plasminogen and plasmin in Alzheimer's disease.
Proteolysis in Alzheimer's disease. Can plasmin tip the balance?
Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains.
Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease.
The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Ameloblastoma
Fibrinolytic activity in cystic lesions of jaw bones.
Amyloidosis
Amyloidosis associated bleeding diatheses in the surgical patient.
Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Anaphylaxis
Anaphylactic shock in dogs. Role of fibrinolysin and vasoactive polypeptide systems.
Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock.
Fibrinolysis and anaphylaxis. I. Activation of blood fibrinolysin during anaphylactic shock in guinea pigs.
Study of fibrinogen and plasminogen concentrations in rabbits during anaphylactic shock.
Anemia
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Lonomia genus caterpillar toxins: biochemical aspects.
Anemia, Sickle Cell
Coagulopathies and arterial stroke.
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta.
Elastase-induced experimental aneurysms in rats.
Fibrinolytic activity of human brain.
Genes predisposing to rapid aneurysm growth.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Molecular analysis of blood vessel formation and disease.
Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
Plasmin and matrix metalloproteinases in vascular remodeling.
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Role of matrix metalloproteinases (MMPs) and MMP inhibitors on intracranial aneurysms: a review article.
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Thrombus versus Wall Biological Activities in Experimental Aortic Aneurysms.
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.
Vascular aneurysms: a perspective.
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Vascular extracellular matrix remodeling in cerebral aneurysms.
Aneurysm, Dissecting
Thrombolytic therapy and acute aortic dissection.
Angina Pectoris
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.
[Newly developed stenocardia: effect of intensive physical training on the indicators of the blood coagulation system and fibrinolysis]
Angina, Stable
Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
Angina, Unstable
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators.
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
[Unstable angina: tissue plasminogen activator, tissue plasminogen activator inhibitors, protein C and other factors of the blood fibrinolytic system]
Angioedema
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema in Stroke Patients With Thrombolysis.
Plasminflammation-An Emerging Pathway to Bradykinin Production.
Protease inhibitors in the treatment of hereditary angioedema.
Angioedemas, Hereditary
A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor.
A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan.
Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.
Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Generation of plasmin during acute attacks of hereditary angioedema.
Hereditary angioedema with a mutation in the plasminogen gene.
Hereditary angioedema.
Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema.
On the pathogenicity of the plasminogen K330E mutation for hereditary angioedema.
Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
Plasminogen activation in hereditary angioneurotic edema.
Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families.
Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma.
Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects.
Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
Anovulation
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Anthracosilicosis
[Effect of fibrinolysin and heparin on the formation of fibrosis in experimental anthracosilicosis]
Anthrax
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Antiphospholipid Syndrome
Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
Coagulopathies and arterial stroke.
Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin.
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice.
Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients.
Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen.
The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen.
[Diagnosis and treatment of coagulation disorders]
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
[The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].
Antithrombin III Deficiency
Coagulopathies and arterial stroke.
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria.
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
[Molecular basis of thrombosis]
Aortic Aneurysm
Doxycycline treatment in a model of early abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Activators of plasminogen and the progression of small abdominal aortic aneurysms.
Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping.
Increased PAI-1 in Females Compared to Males is Protective for Abdominal Aortic Aneurysm Formation in a Rodent Model.
Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes.
Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms.
Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Aortic Diseases
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Aortic Valve Stenosis
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves.
[A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement]
Arrhythmias, Cardiac
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Arterial Occlusive Diseases
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs]
Arteriosclerosis
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta.
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Treatment of experimental pulmonary arteriosclerosis with cortisone, heparin and fibrinolysin.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
[Effect of fibrinolysin on the development of experimental cholesterol arteriosclerosis in rabbits]
[Lipoprotein (a)--a further risk factor in arteriosclerosis?]
[Lypolytic activity of aorta and liver under the effect of fibrinolysin in rabbits with experimental cholesterol arteriosclerosis]
[Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.]
Arteriosclerosis Obliterans
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans.
Arteriovenous Fistula
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis]
Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Arthritis
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Fibrin dissolution in synovial fluid.
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Mini-plasminogen-like fragments of plasminogen in synovial fluid in acute inflammatory arthritis.
Novel aspects and new roles for the serine protease plasmin.
Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.
Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe?
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis.
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Role of plasminogen activator inhibitor - 1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway.
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation.
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
[Experimental plasmin arthritis]
Arthritis, Experimental
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Arthritis, Juvenile
[Disorders of the system of hemostasis in patients with juvenile rheumatoid arthritis and rheumatic fever]
Arthritis, Rheumatoid
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Are plasminogen antibodies in rheumatoid arthritis of pathogenic significance?
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis.
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Lack of effect of tranexamic acid on rheumatoid arthritis.
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.
Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts.
Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Regulation of plasminogen receptors.
Serum antiplasmin and plasmin in rheumatoid arthritis.
Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis.
The primary plasmin inhibitor in rheumatoid synovial fluid.
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
[Experimental plasmin arthritis]
Arthus Reaction
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Aspergillosis
Plasminogen alleles influence susceptibility to invasive aspergillosis.
Asthma
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Cyclic adenosine monophosphate induces plasminogen activator inhibitor-1 expression in human mast cells.
Genetic susceptibility to severe asthma with fungal sensitization.
PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model.
Plasmin system regulation in an ovalbumin-induced rat model of asthma.
Plasminogen Activation by Airway Smooth Muscle is Regulated by Type I Collagen.
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
The plasminogen activation system: new targets in lung inflammation and remodeling.
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.
[Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma]
Astrocytoma
Cytokines regulate plasminogen activation system in astrocytoma cells.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.
Atherosclerosis
A basic study on theglobal coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients.2. Plasminogen activator, plasminogen, a2-macroglobulin in atherosclerosis and endogenous hypertriglyceridaemia.
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
A new hypothesis: possible mechanisms in the involvement of the increased plasminogen activator activity in branching regions of the aorta in the initiation of atherosclerosis.
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
A role of plasminogen in atherosclerosis and restenosis models in mice.
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency.
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton.
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Assembly of plasmin-generating proteins on the surface of human endothelial cells.
Atherogenesis and fibrinogen: historical perspective and current status.
Atherogenesis and vascular calcification in mice expressing the human LPA gene.
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Changes in arterial expression of fibrinolytic system proteins in atherogenesis.
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques.
Current understanding of pathogenesis of coronary artery disease and its future implications.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Effects of lipids on thrombotic mechanisms in atherosclerosis.
Endothelial cell fibrinolytic assembly.
Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.
Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis.
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis.
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.
Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties.
Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes.
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial.
Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice.
Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Lipoprotein(a) and coronary heart disease risk.
Lipoprotein(a) and ischemic heart disease-A causal association? A review.
Lipoprotein(a) as a cardiovascular risk factor: current status.
Lipoprotein(a) as a risk factor for coronary artery disease.
Lipoprotein(a), atherosclerosis and thrombosis.
Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism.
Lipoprotein(a), plasmin modulation, and atherogenesis.
Lipoprotein(a): an emerging cardiovascular risk factor.
Lipoprotein(a): Current Perspectives.
Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.
Molecular analysis of blood vessel formation and disease.
Novel aspects and new roles for the serine protease plasmin.
Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis.
Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?
Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells.
Plasmin and matrix metalloproteinases in vascular remodeling.
Plasmin induces intercellular adhesion molecule 1 expression in human endothelial cells via nuclear factor-?B/mitogen-activated protein kinases-dependent pathways.
Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response.
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Plasminogen activators in vascular remodeling and angiogenesis.
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
Plasminogen inhibits TNFalpha-induced apoptosis in monocytes.
Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study.
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Studies in experimental atherosclerosis. IV. Serum fibrinolysin activity in cholesterol atherosclerosis.
The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels.
The role of the fibrinolytic system in corneal angiogenesis.
Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.
Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus.
[A study of problems of the diagnosis and pathogenesis of atherosclerosis using fibrinolysin labeled with I-131]
[Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.]
[Experimental substantiation of the diagnosis of atherosclerosis by the use of fibrinolysin labeled with I-131]
[Expression of tissue-type plasminogen activator (t-PA) in smooth muscle cells of injured iliac arteries in rabbits]
[Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta]
[Lipids and atherosclerosis]
[Lipoprotein (a) and plasminogen in atherosclerosis]
[Lipoprotein (a). An additional marker of atherosclerosis]
[Lipoprotein(a). Its importance as an additional atherosclerosis marker]
[Lipoprotein(a): a link between thrombogenesis and atherogenesis]
[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?]
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
[Protective effect of combined injection of fibrinolysin and heparin against thrombogenesis in animals during the pre-thrombotic state and in experimental atherosclerosis]
[Relations between fibrinolysis and human atherosclerosis. Tissue activator of plasminogen of the arterial wall]
[Some biochemical indices of the blood under the effect of fibrinolysin in rabbits with experimental cholesterol atherosclerosis]
[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Atrial Fibrillation
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Autoimmune Diseases
A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.
alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci.
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Plasmin as a proinflammatory cell activator.
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
Autoimmune Pancreatitis
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Babesiosis
Blood markers of fibrinolysis and endothelial activation in canine babesiosis.
Bacteremia
Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).
Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia.
Immobilization of plasminogen on Escherichia coli flagella.
Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks.
Bacterial Infections
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Procalcitonin and Other Biomarkers of Sepsis in Newborns in the Intensive Care Unit.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
The interaction of two novel putative proteins of Leptospira interrogans with E-cadherin, plasminogen and complement components with potential role in bacterial infection.
Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.
beta-Thalassemia
Impact of ?-thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension.
Blister
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes.
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Fibrinolysis inhibition in human burn blister fluid.
Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
The extra-articular deposition of fibrinogen antigenic material in patients with rheumatoid arthritis.
[Coagulation factors in human born blisters (author's transl)]
Bone Diseases
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.
Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.
Bone Resorption
Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Effects of plasminogen and interleukin-1 beta on bone resorption in vitro.
Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency.
Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-beta, IL-1 alpha and EGF in fetal rat calvaria cells at different times of culture.
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones.
The role of the plasminogen system in bone resorption in vitro.
Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane.
Brain Diseases
Cellular mechanisms regulating non-haemostatic plasmin generation.
[Change in the concentration of plasmin and its inhibitors in the blood of patients with dyscirculatory encephalopathy before and after treatment]
Brain Edema
Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Plasminogen activators potentiate thrombin-induced brain injury.
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat.
Brain Infarction
[Revising the principles and improving the methods of differential therapy of ischemic stroke]
Brain Injuries
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury.
Plasminogen activators potentiate thrombin-induced brain injury.
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
[The permeability of the hemato-encephalic barrier and the proteolytic potential of the cerebrospinal fluid in severe craniocerebral trauma]
Brain Injuries, Traumatic
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Fibrinolysis: from blood to the brain.
Genotype and Injury Effect on the Expression of a Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 (SRPX2).
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Traumatic brain injury: Tissue-type plasminogen activator-harmful or beneficial?
Brain Ischemia
Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity.
Cerebral ischemia and neuroregeneration.
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia.
GSK-3? as a target for protection against transient cerebral ischemia.
Intracerebral transplantation of bone marrow stromal cells ameliorates tissue plasminogen activator-induced brain damage after cerebral ischemia in mice detected by in vivo and ex vivo optical imaging.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Plasminogen activation in experimental permanent focal cerebral ischemia.
Plasminogen activation in focal cerebral ischemia and reperfusion.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice.
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Brain Neoplasms
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Brain tumors and plasmin inhibitors.
Genes Encoding Mammalian Oviductal Proteins Involved in Fertilization are Subjected to Gene Death and Positive Selection.
Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Plasma fibrinolytic profile in patients with brain tumors.
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
[A plasminogen regulation system in brain tumors].
Brain Stem Infarctions
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Breast Cyst
Breast cyst fluid plasmin activity and its effect on TGF-beta2 activation.
Urokinase and tissue-type plasminogen activators are present in breast cyst fluids.
Breast Diseases
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Breast Neoplasms
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Association of plasminogen activator activity and steroid receptors in human breast cancer.
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.
Characteristics of fibrinolysin secreted by cultured rat breast carcinoma cells.
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.
Evidence for the clinical use of tumour markers.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Factors involved in the plasminogen activation system in human breast tumours.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Functional evaluation of plasmin formation in primary breast cancer.
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen.
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.
Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.
Pathway-Based Biomarker Search by High-Throughput Proteomics Profiling of Secretomes.
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.
Plasmin induces the formation of multicellular spheroids of breast cancer cells.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
Proteases as prognostic markers in cancer.
Proteolysis of CCN1 by plasmin: functional implications.
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Sanguisorba minor extract suppresses plasmin-mediated mechanisms of cancer cell migration.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Sialylated Lewis x Antigen Bearing Glycoproteins in Human Plasma.
Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion.
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
Synthetic substrates specific to activated plasmin can monitor the enzymatic functional status in situ in breast cancer cells.
Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer.
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer.
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Tissue plasminogen activators in breast cancer.
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
[A plasminogen regulation system in brain tumors].
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue]
[The immunoenzyme determination of plasminogen activators and their inhibitor in breast tumors: the connection to clinico-morphological prognostic factors]
Bronchiectasis
Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo.
Bronchiolitis
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Bronchitis
[Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading]
Budd-Chiari Syndrome
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Bundle-Branch Block
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
[Fibrinolysis or angioplasty in acute myocardial infarction?]
Carcinogenesis
Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype.
Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.
Helicobacter pylori interactions with plasminogen.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.
The interplay between hemostasis and malignancy: the oral cancer paradigm.
The molecular biology of colorectal cancer development and the associated genetic events.
The plasminogen activator inhibitor "paradox" in cancer.
The role of plasmin in the pathogenesis of murine multiple myeloma.
Three are better than one: plasminogen receptors as cancer theranostic targets.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
[Endothelial cell proteases and their modulation by platelets]
Carcinoma
A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas.
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity.
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Alterations in fibrinogen, plasminogen, and inhibitors of plasmin with the growth of V2 carcinoma in rabbits.
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (Shionogi SC-115 cells) in vitro.
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells.
Angiostatin generation by human pancreatic cancer.
Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis.
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas.
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases.
Circulating fibrinolysin in carcinoma of the prostate.
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats.
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Expression and activation of proteases in co-cultures.
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Expression of plasminogen activators in basal cell carcinoma.
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Fibrinolytic activity of in vitro cultivated human bladder cell lines.
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN.
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase.
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Isolation and spontaneous transformation of cloned lines of hamster tracheal epithelial cells.
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen activators in oesophageal carcinoma.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Plasminogen receptors on rat colon carcinoma cells.
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Proteolytic patterns of head and neck squamous cell carcinoma.
Receptor for plasmin on human carcinoma cells.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Relationship between plasminogen activators and stomach carcinoma stage.
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells.
Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
The accumulation of angiostatin-like fragments in human prostate carcinoma.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines.
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Visualization of the plasmin receptor on carcinoma cells.
Visualization of the plasmin receptor on sections of human mammary carcinoma cells.
Vitronectin in human breast carcinomas.
[Behavior of plasminogen in prostatic carcinoma treated with cytonal]
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Carcinoma in Situ
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Carcinoma, Basal Cell
Expression of plasminogen activators in basal cell carcinoma.
Carcinoma, Bronchogenic
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma, Brown-Pearce
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Carcinoma, Ehrlich Tumor
Action of antibodies and plasmin on Ehrlich ascites tumour cells.
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Plasmin regulating system from embryonal carcinoma F9 cells: plasminases A, B and embrinogen.
Carcinoma, Hepatocellular
Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1.
Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence.
Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells.
Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice.
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.
Kringle 5 of Human Plasminogen Suppresses Hepatocellular Carcinoma Growth Both in Grafted and Xenografted Mice by Anti-Angiogenic Activity.
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.
Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).
Regulation of plasminogen gene expression by interleukin-6.
Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation.
The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation.
Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
[Clinical studies of serum protease inhibitors in hepatoma]
[Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma]
Carcinoma, Lewis Lung
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Carcinoma, Non-Small-Cell Lung
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Carcinoma, Papillary
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Carcinoma, Renal Cell
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Carcinoma, Squamous Cell
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Proteolytic patterns of head and neck squamous cell carcinoma.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
Carcinoma, Transitional Cell
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinosarcoma
The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.
The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood.
Cardiomyopathies
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Exercise-induced hemostatic activation in patients with dilated cardiomyopathy in sinus rhythm.
Cardiovascular Diseases
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Alcohol, heart disease, and mortality: a review.
Biochemistry of protein tyrosine nitration in cardiovascular pathology.
Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up.
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Molecular analysis of blood vessel formation and disease.
New developments in thrombolytic therapy.
Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
Plasminogen activator system and vascular disease.
Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
Recent developments in depsipeptide research.
Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease.
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
The functions of plasminogen in cardiovascular disease.
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
[Biochemical markers of endothelial dysfunction and cardiovascular system state in patients with occupationai bronchopulmonary diseases].
Caroli Disease
Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease.
Carotid Artery Diseases
Hemostatic function and carotid artery disease.
Carotid Artery Injuries
Endoluminal arterial injury in plasminogen-deficient mice.
Carotid Artery Thrombosis
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis.
Catalepsy
Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Cataract
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery.
[Densitometric analysis of changes in the vitreous body after cataract extraction]
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery]
Celiac Disease
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Central Nervous System Diseases
Interventional use of plasminogen activators in central nervous system diseases.
Cerebral Amyloid Angiopathy
An Enzyme from Aristolochia indica Destabilizes Fibrin-? Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
Cerebral Hemorrhage
An emerging role of mast cells in cerebral ischemia and hemorrhage.
Antithrombotic treatments in acute ischemic stroke.
Blood-brain barrier disruption by low-frequency ultrasound.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Comparative safety of thrombolytic agents.
Coronary artery disease, myocardial infarction, and brain embolism.
Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage.
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke.
Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Role of tissue-type plasminogen activator in ischemic stroke.
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
The Effects of the Contact Activation System on Hemorrhage.
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Thrombolytic therapies: the current state of affairs.
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Cerebral Infarction
Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke.
Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis.
Hematologic abnormalities occur in both cortical and lacunar infarction.
Hemorrhagic complications of thrombolytic therapy in experimental stroke.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Polymorphism of plasminogen in healthy individuals and patients with cerebral infarction.
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
[Frequency and clinical significance of congenital plasminogen abnormality in cerebral infarction]
Cerebrovascular Disorders
A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
Congenitally abnormal plasminogen in juvenile ischemic cerebrovascular disease.
Fibrinolysin in cerebrovascular diseases.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Therapeutic problems in cerebrovascular disease. The experimental use of plasmin in dogs.
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Chagas Disease
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Charcot-Marie-Tooth Disease
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholelithiasis
[Hemostatic indices of oncological patients with different forms of jaundice]
Cholera
Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells.
Cholestasis
Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis.
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Cholesteatoma, Middle Ear
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Choriocarcinoma
Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
Choroidal Neovascularization
Anti-inflammatory and anti-angiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.
Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
[Intravitreal injection. Drugs to treat subretinal hemorrhage].
Chronic Periodontitis
Neutrophil elastase is involved in the initial destruction of human periodontal ligament.
Plasmin is essential in preventing periodontitis in mice.
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
coagulation factor xia deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Coinfection
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Colic
Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Colitis
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Colitis, Ulcerative
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Colonic Diseases
Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.
Colonic Neoplasms
Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway.
Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells.
Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential.
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells.
Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer.
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway.
[Protease activities in gastric and colon cancer tissues]
Colorectal Neoplasms
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Differences in the activation mechanism between the alpha and beta subunits of human meprin.
Evidence for the clinical use of tumour markers.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Plasminogen activation system and colorectal cancer biology.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic role of tumor-associated proteases in colorectal cancer.
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Role of urokinase in colorectal neoplasia.
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Tumor associated proteases -- prognostic markers of colorectal cancer.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Coma
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Communicable Diseases
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Congenital Abnormalities
Clinical application of fibrinolysis laboratory tests: a review.
Clinical disorders of fibrinolysis: a critical review.
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
[Congenital abnormality of plasminogen]
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Conjunctivitis
Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature.
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis.
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis.
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Difficulties in mutation screening of the plasminogen (PLG) gene in patients with ligneous conjunctivitis and severe hypoplasminogenemia.
Difficulties in the mutation analysis of plasminogen gene: a study in two patients with ligneous conjunctivitis.
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog.
Fresh frozen plasma (Octaplas) and topical heparin in the management of ligneous conjunctivitis.
Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature.
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis.
Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.
Letter Regarding "Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature" by Y. Tu et al.
Ligneous conjunctivitis due to plasminogen deficit: Diagnostic and therapeutic approach. With literature review.
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report.
Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency.
Ligneous conjunctivitis in a Mexican patient with a mutation in the plasminogen (PLG) gene.
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Ligneous conjunctivitis in a young patient with homozygous K19E plasminogen gene mutation: a diagnostic and therapeutic challenge.
Ligneous conjunctivitis in plasminogen-deficient mice.
Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog.
Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level.
Ligneous conjunctivitis with plasminogen deficiency.
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Ligneous conjunctivitis.
Ligneous conjunctivitis: a clinicopathological, immunohistochemical, and genetic study including the treatment of two sisters with multiorgan involvement.
Ligneous conjunctivitis: a local manifestation of a systemic disorder?
Ligneous periodontitis in a child with plasminogen deficiency.
Long-term efficacy of surgical removal of pseudomembranes in a child with ligneous conjunctivitis treated with plasminogen eyedrops.
Management of hydrocephalus in children with plasminogen deficiency.
Management of ligneous conjunctivitis in a child with plasminogen deficiency.
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis.
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Otolaryngological manifestations of ligneous conjunctivitis.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Plasminogen deficiency.
Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency.
Retraction: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in An 8-Week-Old Female Infant.
Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis.
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency.
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis.
Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant.
Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen.
[Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature]
[Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)]
Conjunctivitis, Allergic
Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Conjunctivitis, Bacterial
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Connective Tissue Diseases
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Corneal Diseases
Elevation of tear fluid plasmin in corneal disease.
Corneal Injuries
Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair.
Enzyme histochemistry of corneal wound healing.
The histochemical pattern of mechanically or chemically injured rabbit cornea after aprotinin treatment: relationships with the plasmin concentration of the tear fluid.
Corneal Neovascularization
Acidic/Neutral Amino Acid Residues Substitution in NH2 Terminal of Plasminogen Kringle 5 Exerts Enhanced Effects on Corneal Neovascularization.
Anti-angiogenic role of angiostatin during corneal wound healing.
Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization.
Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas.
Plasmin and epidermal growth factor in the tear fluid of contact-lens wearers: effect of wearing different types of contact lenses and association with clinical findings.
Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin.
The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF.
The role of the fibrinolytic system in corneal angiogenesis.
Towards a closed eye model of the pre-ocular tear layer.
[Fibrinolysis components and angiogenesis regulation by example of burn-induced corneal neovascularization in rabbits].
Corneal Opacity
[Etiology of corneal opacities after plasminogen activator-induced fibrinolysis of the anterior chamber]
Corneal Ulcer
Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy.
Coronary Aneurysm
Decreased plasminogen activator inhibitor-1 levels in coronary artery aneurysmatic patients.
Coronary Artery Disease
Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.
Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.
Inflammation, the endothelium, and the acute coronary syndromes.
Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
Plasminogen and fibrinogen plasma levels in coronary artery disease.
Plasminogen and plasmin activity in patients with coronary artery disease.
Plasminogen levels and risk of coronary artery disease.
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Severity of coronary artery disease and basal fibrinolysis.
The interactions between hemostasis and resistance training: a review.
The peculiar evolution of apolipoprotein(a) in human and rhesus macaque.
Thrombin and plasmin activity in coronary artery disease.
Urokinase plasminogen activator system in humans with stable coronary artery disease.
[The use of heparin and fibrinolysin in patients with coronary arteriosclerosis]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Disease
Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene.
Lipid-thrombosis interface.
The effect of exercise on thrombin and plasmin generation in middle-aged men.
[A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease]
[Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Occlusion
Intracoronary thrombolysis in evolving myocardial infarction.
[Blood coagulation shifts in patients with myocardial infarction treated with streptokinase]
Coronary Stenosis
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.
Coronary Thrombosis
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
FIBRINOLYSIN AND ITS RELATION TO THE MANAGEMENT OF CORONARY THROMBOSIS.
Novel antithrombotic approaches to coronary artery disease.
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Role of nitrates in acute myocardial infarction.
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
Cowpox
The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Craniocerebral Trauma
[The possible mechanisms of a fibrinolytic disorder in patients with severe craniocerebral trauma]
Creutzfeldt-Jakob Syndrome
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Crohn Disease
Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Cushing Syndrome
Further studies on the hypercoagulable state of patients with Cushing's syndrome.
Cystic Fibrosis
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Cysts
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs.
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Cytomegalovirus Infections
Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells.
Darier Disease
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies.
Darier's disease: an immunohistochemical study using antibodies to proteases.
Death, Sudden, Cardiac
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene.
Dehydration
Expression, purification, and biological characterization of Anaplasma phagocytophilum enolase.
Stress down regulates milk yield in cows by plasmin induced beta-casein product that blocks K+ channels on the apical membranes.
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Dementia, Vascular
Plasminogen and plasmin in Alzheimer's disease.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Demyelinating Diseases
Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination.
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Plasminogen activator activity and plasmin inhibition in nerves.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
Tissue plasminogen activator gene expression in multiple sclerosis brain tissue.
Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
Dengue
Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity.
Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Dengue Virus Nonstructural Protein 1-Induced Antibodies Cross-React with Human Plasminogen and Enhance Its Activation.
Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation.
Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.
GRP78: a multifunctional receptor on the cell surface.
Modulation of ?-enolase post-translational modifications by dengue virus: increased secretion of the basic isoforms in infected hepatic cells.
Participation of the Dengue virus in the fibrinolytic process.
Peptide Bbeta(15-42) preserves endothelial barrier function in shock.
Dental Plaque
Cellular source, activation and inhibition of dental plaque collagenase.
Plasminogen binding by oral streptococci from dental plaque and inflammatory lesions.
Relationship between fibrinolytic activity and gingival inflammatory reaction in young individuals.
Dermatitis
The effect of tamol on human mast cell chymase and plasmin.
Dermatitis, Atopic
Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis.
Plasminogen activators and antiplasmin activity in atopic dermatitis.
Dermatomyositis
Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).
Diabetes Complications
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Diabetes Mellitus
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors.
Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen.
Plasminogen activation in diabetes mellitus: kinetics of plasmin formation with plasminogen and tissue plasminogen activator from diabetic donors.
Plasminogen activation in diabetes mellitus: normalization of blood sugar levels improves impaired enzyme kinetics in vitro.
Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.
Risk Factors for Thrombosis Development in Mexican Patients.
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control.
[Effect of venous stasis on plasminogen activation and plasma alpha 2-antiplasmin levels in type II diabetes mellitus]
[Lipoprotein and plasminogen serum levels in patients with diabetes mellitus type 2: risk factors for macroangiopathy? Preliminary study]
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
[Plasma fibrinopeptide A, fibrinopeptide B beta 15-42 and 4 other coagulation factors levels in patients with diabetic retinopathy]
[Plasminogen activation and erythrocyte aggregation in diabetic patients]
Diabetes Mellitus, Type 1
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Hemostatic variables in Arab diabetics.
Diabetes Mellitus, Type 2
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Blood coagulation and fibrinolysis in obese NIDDM patients.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria.
Hemobiological properties of gliclazide.
Hemostatic variables in Arab diabetics.
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)]
Diabetic Foot
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Diabetic Nephropathies
Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy.
Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma.
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
[Effects of shear stress on expression of plasminogen activator (tPA and uPA) in cultured kidney proximal tubular epithelial cells and its significance]
[Lipid metabolism and fibrinolysis in diabetic nephropathy in the course of diabetes type II]
[Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC]
[The vascular wall and fibrinolysis--pathologic aspects]
[Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy]
Diabetic Retinopathy
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Autologous plasmin enzyme in the surgical management of diabetic retinopathy.
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.
Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Pharmacologic Vitreolysis in Diabetic Retinopathy.
Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man.
uPA, tPA and PAI-1 mRNA expression in periretinal membranes.
[Studies on diabetic retinopathy and plasmin activity in the blood (with reference to duration and blood sugar)]
Diphtheria
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Disseminated Intravascular Coagulation
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Acute generalized, widespread bleeding. Diagnosis and management.
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.
Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase.
Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin.
Consumption coagulopathy associated with shock in acute African swine fever.
Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation.
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated intravascular coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs.
Effect of urokinase on disseminated intravascular coagulation.
Effects of intravenous infusion of human prostate tissue substances in dogs.
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Experimental study of rabbit fibrinogen degradation products. Influence of plasminogen level for the interpretation of serum concentration of fibrinogen degradation products in consumption coagulopathies.
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation.
Fibrinolysis in disseminated intravascular coagulation.
Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis.
Hematin: unique effects of hemostasis.
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
New rapid assay for factor XIa-alpha 1 antitrypsin complex--application to DIC.
Pathways of coagulation/fibrinolysis activation in malignancy.
Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.
Postoperative bleeding in a patient with normal screening coagulation tests.
Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine.
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Treatment of severe acute respiratory distress syndrome: a final report on a phase I study.
Vitamin K reduces bleeding in left ventricular assist device recipients.
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
[Protease inhibitors and plasminogen in leukemia--with special reference to disseminated intravascular coagulation (author's transl)]
[Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)]
Down Syndrome
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Nerve growth factor metabolic dysfunction in Down's syndrome brains.
Dry Eye Syndromes
Tear fluid plasmin activity of dry eye patients with Sjögren's syndrome.
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Dry Socket
Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Duodenal Ulcer
Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
[Vascular component of the fibrinolytic system of blood (plasminogen activator of vascular wall) in patients with duodenal ulcer with a history of hemorrhagic complications]
Dysentery
[Activity of the plasmin enzymatic system and of serum hyaluronidase in dysentery]
[Correlations of the level of plasmin system and blood serum hyaluronidase activity with pathology of the large intestine in dysentery]
Dyslipidemias
Dyslipidemia and the risk of Alzheimer's disease.
Impaired fibrinolytic activity is present in children with dyslipidemias.
Metabolic abnormalities in hypertension.
Ehlers-Danlos Syndrome
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Embolism
Fibrinolysin (Actase) in the treatment of peripheral embolism.
Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats.
LYSIS OF THE EXPERIMENTAL RADIOACTIVE PULMONARY EMBOLUS INDUCED BY STREPTOKINASE AND SK-ACTIVATED PLASMIN.
Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Thrombolytic effect of tissue plasminogen activator in a cerebral embolic model.
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
[Lipoprotein(a): structure, metabolism and atherosclerotic disease]
[Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs]
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
[Treatment of thrombosis and embolisms with human fibrinolysin.]
Embolism and Thrombosis
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Embolism, Cholesterol
Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Empyema
Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study.
Encephalitis
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Encephalitis, Herpes Simplex
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Encephalomyelitis
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Encephalomyelitis, Autoimmune, Experimental
Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
Endarteritis
Can the activation of plasminogen/plasmin system of the host by metabolic products of Dirofilaria immitis participate in heartworm disease endarteritis?
Fibrinolysis and proliferative endarteritis: two related processes in chronic infections? The model of the blood-borne pathogen Dirofilaria immitis.
Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system.
Endemic Diseases
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Endocarditis
Activation of plasminogen by Streptococcus mutans.
Antibiotic modulation of the plasminogen binding ability of viridans group streptococci.
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endocarditis, Non-Infective
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endometrial Hyperplasia
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma.
High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma.
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometriosis
A role for the fibrinolytic system in postsurgical adhesion formation.
Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease.
Fibrinolytic properties of peritoneal fluid in endometriosis.
Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation.
Local activation of TGF-beta1 at endometriosis sites.
Plasminogen activators and plasminogen activator inhibitors in endometriosis.
Plasminogen activators in endometriosis.
Endometritis
Involvement of the plasminogen activation system in cow endometritis.
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Endotoxemia
Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.
Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia.
Interaction of leukocytes and endotoxin with the plasmin and kinin systems.
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
Eosinophilia
Plasminogen levels in subjects with eosinophilia.
Epidermolysis Bullosa Dystrophica
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Epilepsy, Rolandic
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.
Epiretinal Membrane
Plasminogen activation in epiretinal membranes.
Plasminogen in proliferative vitreoretinal disorders.
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
[Enzymatic vitrectomy by intravitreal autologous plasmin injection as initial treatment for macular epiretinal membranes and vitreomacular traction syndrome.]
[Thrombospondin and its importance in proliferative retinal diseases]
Esophageal Neoplasms
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Serine proteinase activation in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Essential Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Fibrinolytic system in normotensive subjects and hypertensive patients.
Haemostatic variables in arterial hypertension.
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction]
[Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension: the effect of atenolol (author's transl)]
[The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension].
Exostoses
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Eye Diseases
A study of plasmin in eye disease.
Eye Hemorrhage
[Mechanism of action of fibrinolysin and a verification of the efficacy of its use in traumatic hemophthalmos]
[Phonophoresis of fibrinolysin and potassium iodide in complex treatment of hemophthalmos]
Eye Infections
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Fabry Disease
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.
Factor V Deficiency
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Factor XI Deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Factor XII Deficiency
Chloroform-induced fibrinolysis. Its dependence on Hageman factor, plasma prekallikrein, and high molecular weight kininogen.
Factor XIII Deficiency
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Familial Mediterranean Fever
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
Familial Primary Pulmonary Hypertension
A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension.
Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences.
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension.
Fatty Liver
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.
Febrile Neutropenia
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Fetal Alcohol Spectrum Disorders
Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain.
Fetal Death
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
Fetal Growth Retardation
Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Fibroadenoma
Factors involved in the plasminogen activation system in human breast tumours.
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrocystic Breast Disease
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrosarcoma
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells.
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells.
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor.
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Follicular Cyst
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Foot Ulcer
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Fuchs' Endothelial Dystrophy
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Galactosemias
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Gastritis
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.
Gastrointestinal Neoplasms
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
gelatinase b deficiency
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Giant Cell Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Giardiasis
Insights into the Giardia intestinalis enolase and human plasminogen interaction.
Gingival Hyperplasia
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Periodontitis associated with plasminogen deficiency: a case report.
Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report.
Gingival Overgrowth
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Gingivitis
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
Ligneous alveolar gingivitis in the absence of plasminogen deficiency.
Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis.
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Successful treatment of ligneous gingivitis with warfarin.
Glaucoma
Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin.
Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
[Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy].
[Use of fibrinolysin after microsurgical operations for glaucoma]
Glaucoma, Open-Angle
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.
Glioblastoma
Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Antifibrinolytic therapy of experimentally grown malignant brain tumors.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.
Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
[A plasminogen regulation system in brain tumors].
Glioma
Annexin A2 promotes glioma cell invasion and tumor progression.
Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro.
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Endothelial cell-derived plasmin promotes human glioma cell proliferation.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Expression of plasminogen receptors on C6 glioma cells.
High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1-5-containing fragments.
Hyaluronic acid facilitates glioma cell invasion in vitro.
Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin.
Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3.
Investigation of serum proteome alterations in human glioblastoma multiforme.
Lithium chloride inhibits thrombin-induced intracellular calcium mobilization in C6 rat glioma cells.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Plasmin modulates the thrombin-evoked calcium response in C6 glioma cells.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes.
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
Protease nexin 1 is expressed in the human placenta.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
The role of the plasminogen activation cascade in glioma cell invasion: a review.
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
[Biological profiles of malignant gliomas]
[Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture]
Glomerulonephritis
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis.
Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat.
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis.
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.
Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Urinary plasminogen and chronic glomerulonephritis.
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
[The effect of membrane-stabilizing therapy on the status of the hemostatic system in patients with glomerulonephritis with a hematuric component]
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
[Urinary excretion of plasmin and fibrin-fibrinogen degradation products in various types of glomerulonephritis (author's transl)]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Role of tubulointerstitial plasmin in the progression of IgA nephropathy.
Glomerulonephritis, Membranous
A novel autoantibody to plasminogen and its characterization in Heymann nephritis.
Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen GP330.
Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330.
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen.
Glomerulosclerosis, Focal Segmental
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Glucose Intolerance
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Goiter
[Thyroid tissue link of hemostasis in diffuse toxic and euthyroid goiter]
Gout
Fibrin dissolution in synovial fluid.
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Graft vs Host Disease
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.
Granuloma
An immunoperoxidase study of immunological factors in high immune and low resistance granulomas in leprosy.
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
The monocyte-macrophage system in granulomatous inflammation.
Gray Platelet Syndrome
Plasminogen interacts with human platelets through two distinct mechanisms.
Guillain-Barre Syndrome
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Hamartoma
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
Hearing Loss
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
[A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy]
Hearing Loss, Sensorineural
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Asymmetric sudden sensorineural hearing loss: is all this testing necessary?
Heart Arrest
Pediatric In-Hospital Cardiac Arrest Secondary to Acute Pulmonary Embolism.
Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model.
Pulmonary thromboembolism after carbon monoxide poisoning.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Heart Block
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis.
Heart Diseases
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Apolipoproteins(a): a puzzling evolutionary story.
Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels.
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.
Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease.
Pre- and post-operative studies of fibrinolysis and prothrombin in cyanotic congenital heart disease.
Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]
Heart Failure
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart.
Prevention of incipient diabetic cardiomyopathy by high-dose thiamine.
Heart Rupture
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Hemangioma
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Hemarthrosis
Does Tranexamic Acid Reduce Knee Swelling and Improve Early Function Following Arthroscopic Meniscectomy? A Double-Blind Randomized Controlled Trial.
Hematocolpos
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Hematologic Diseases
[Study of hemostasis in patients with a recent thromboembolic complication]
Hematologic Neoplasms
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].
Hematoma, Subdural
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Hematoma, Subdural, Chronic
Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot.
Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Tissue-type plasminogen activator in the chronic subdural hematoma.
Hemoglobinuria
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemoglobinuria, Paroxysmal
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemolytic-Uremic Syndrome
Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells.
Hemophilia A
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Fibrinolysin studies in hemophilia.
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
THE ROLE OF FIBRINOLYSIN AND PROFIBRINOLYSIN ACTIVATOR IN HEMOPHILIA.
Therapies for the treatment of abnormal uterine bleeding.
[Evaluation of the results of studying fibrinase in patients with hemophilia A]
Hemorrhagic Disorders
A single thymine nucleotide deletion responsible for congenital deficiency of plasmin inhibitor.
Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Studies on the plasminogen proactivator of plasma in children with hemorrhagic disorders.
Hemorrhagic Fever with Renal Syndrome
Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
[A dynamic study of plasminogen, antithrombin III, fibrinogen and DIC in epidemic hemorrhagic fever]
[Detection of plasma AT-III and plasminogen in patients with epidemic hemorrhagic fever and its clinical significance]
Hemothorax
STUDY OF FIBRINOLYSIN ON CLOTTED HEMOTHORAX.
Treatment of clotted hemothorax with fibrinolysin.
[Coagulative and fibrinolytic properties of blood effused into the pleural cavity after lung surgery]
Hepatic Insufficiency
Plasminogen abnormalities in patients with Argentine hemorrhagic fever.
[The disorders of hemostasis system and thrombotic complications in oncologic patients having liver operation.]
Hepatic Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator?
Hepatitis
Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Bilirubin or plasminogen--which is better in the assessment of the severity of viral hepatitis?
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Potency of fragmented IgG: two studies of postexposure prophylaxis in type A hepatitis.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis.
[Diagnostic value of plasminogen in viral hepatitis]
[Reduced fibrinolysin activity in fatal epidemic hepatitis.]
Hepatitis A
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis.
Robustness of nanofiltration for increasing the viral safety margin of biological products.
Hepatitis B
Contributions to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives.
Immunohistological investigations of PAS-negative globular intracisternal hyalin in human liver biopsy specimens.
Hepatitis C
Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers.
Monitor.
Hepatitis E
Hepatitis E virus open reading frame 3 protein interacts with porcine liver-specific plasminogen and ?2-antiplasmin.
Hepatitis, Chronic
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
[The activity of fibrinase in cirrhosis of the liver and chronic hepatitis]
Hepatolenticular Degeneration
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Herpes Simplex
Herpesviruses enhance fibrin clot lysis.
Herpes Zoster
Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator.
Effects of plasmin on sperm-oocyte interactions during in vitro fertilization in the pig.
How Is Plasminogen/Plasmin System Contributing to Regulate Sperm Entry Into the Oocyte?
Localization of plasminogen in the extracellular matrix of hamster eggs: exogenous activation by streptokinase.
nompA encodes a PNS-specific, ZP domain protein required to connect mechanosensory dendrites to sensory structures.
Plasminogen detection in oocytes and plasminogen activator activities in the porcine oviduct during the estrous cycle.
The effects of plasminogen on in vitro ovine embryo development.
Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of invitro but not of invivo fertilisation in the mouse.
Histiocytosis, Langerhans-Cell
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
Hodgkin Disease
PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE.
Homocystinuria
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Huntington Disease
Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington's disease caudate nucleus.
Hyaline Membrane Disease
Ontogeny of fibrinolysin system and its role in pathogenesis of hyaline membrane disease of infants.
Plasminogen in the prevention of hyaline membrane disease.
Prevention of hyaline membrane disease with plasminogen. A cooperative study.
Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study.
Studies on hyaline membrane disease. I. The fibrinolysin system in pathogenesis and therapy.
STUDIES ON HYALINE MEMBRANE DISEASE. II. THE ONTOGENY OF THE FIBRINOLYSIN SYSTEM.
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.
[Treatment of hyaline membrane disease with the plasminogen urokinase combination]
Hydatidiform Mole
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Hydrocephalus
Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus.
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Management of hydrocephalus in children with plasminogen deficiency.
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
The ventriculocholecystic shunt: two case reports and a review of the literature.
[Fibrinolytic treatment of cerebral intraventricular hemorrhage]
Hydronephrosis
Causes of venous thrombosis in fifty Chinese patients.
Hydronephrosis is associated with elevated plasmin in urine in pediatric patients and rats and changes in NCC and ?-ENaC abundance in rat kidney.
Hyperalgesia
The p75 receptor is associated with inflammatory thermal hypersensitivity.
Hypercholesterolemia
Cardiovascular issues in hypogonadism and testosterone therapy.
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hyperglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. I. The effect of alloxan-induced hyperglycemia.
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
Hyperhomocysteinemia
Coagulopathies and arterial stroke.
Prothrombotic disorders and ischemic stroke in children.
Thrombophilic screening in retinal artery occlusion patients.
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Hyperinsulinism
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
Metabolic abnormalities in cardiac ischemia.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Hyperkalemia
Deterioration of Kidney Function by the (Pro)renin Receptor Blocker Handle Region Peptide in Aliskiren-treated Diabetic Transgenic (mRen2)27 Rats.
Hyperlipidemias
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease.
Hyperlipemia, fibrinolysis and arteriosclerosis.
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
[Hemostasis profiles in thrombotic disease]
[Hemostatic changes during pregnancy in reference to hyperlipidemia]
Hyperlipoproteinemias
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb]
Hyperpigmentation
Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
Hypersensitivity
Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites.
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries.
Rapid appearance of plasmin in tear fluid after ocular allergen exposure.
Review and application of serine protease inhibition in coronary artery bypass graft surgery.
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
[Allergic reactions to fibrinolysin]
[On the role of plasmin in the mechanism of allergy.]
[Round table conference. V. Plasmin and allergy]
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
Hypersensitivity, Delayed
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Advances in diabetes for the millennium: the heart and diabetes.
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Comparison of plasma total plasmin activities in male and female hypertensive rats.
Correlation between family history of hypertension and haemostatic disorders.
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity.
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Haemostatic parameters in patients with primitive venous hypertension.
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
Is urinary excretion of plasminogen associated with development of pre-eclampsia? An observational, explorative case-control study.
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10?years of follow-up.
Mechanisms of renal NaCl retention in proteinuric disease.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers.
Risk Factors for Thrombosis Development in Mexican Patients.
The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition.
The endocrine function of adipose tissue: an update.
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients.
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
[Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension]
[Effect of heparin on the fibrinase activity of the blood in patients with hypertension]
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
[Neurology in the 21st century--the era of preventive neurology utilizing new diagnostic and therapeutic techniques]
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
[The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]
Hypertension, Pregnancy-Induced
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
Hypertension, Pulmonary
Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension.
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
High Fibrinogen Plus Low Plasminogen Levels Predict Poor Post-Surgical Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension.
Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
[High-altitude pulmonary hypertension and fibrinolysis]
Hyperthyroidism
Coagulation and fibrinolysis in thyroid disease.
Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment.
[Disorders of hemostasis in dysthyroidism]
Hypertriglyceridemia
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Hypertrophy, Left Ventricular
Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy.
[The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients]
Hypertrophy, Right Ventricular
Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload.
Hyphema
Fibrinolysin irrigation in traumatic secondary hyphema.
Fibrinolysis and hyphema. The effect of thrombolysin and Kabikinas on clotted blood in camera anterior of the eye in rabbits.
Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Treatment of total hyphema with fibrinolysin.
[Thrombolytic effect of plasmin, miniplasmin and fibrinolysin in simulated intraocular hemorrhage]
[Treatment of experimental hyphema in rabbits by Sevac plasmin]
[TREATMENT OF TOTAL HYPHEMAS OF THE ANTERIOR CHAMBER WITH FIBRINOLYSIN.]
Hypoglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. II. The effect of insulin induced hypoglycemia.
Hypogonadism
Cardiovascular issues in hypogonadism and testosterone therapy.
Hypotension
A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis.
Acute blood pressure effects of selected serine proteases in normotensive rats and dogs.
Acute haemodilution and prostaglandin E1-induced hypotension: effects on the coagulation-fibrinolysis system.
[ROLE OF PLASMIN IN PEPTONE-INDUCED ARTERIAL HYPOTENSION IN RATS.]
Hypothyroidism
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma.
Hypoxia-Ischemia, Brain
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia.
[Changes and significance of endogenous tissue plasminogen activators in cerebral hypoxia-ischemia in neonatal rats]
Idiopathic Pulmonary Fibrosis
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces.
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
Immunoglobulin G4-Related Disease
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Infant, Newborn, Diseases
Studies on the ontogeny and significance in neonatal disease of the fibrinolysin system and of fibrin stabilizing factor.
Infarction, Middle Cerebral Artery
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Mechanistic insight into Neurotoxicity of Tissue Plasminogen Activator-Induced Thrombolysis Products in a Rat Intraluminal Middle Cerebral Artery Occlusion Model.
Plasminogen activation in focal cerebral ischemia and reperfusion.
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
The Effects of the Contact Activation System on Hemorrhage.
Thrombolysis with plasmin: implications for stroke treatment.
[Evaluation for antithrombotic agents by a thrombotic model in animals].
Infections
A rapid fluorometric assay for tear fluid plasmin activity.
A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice.
Acquisition of the Sda1-encoding bacteriophage does not enhance virulence of the M1 Streptococcus pyogenes strain SF370.
Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection.
Analysis of plasminogen-binding M proteins of Streptococcus pyogenes.
Babesia bovis (= argentina): changes in erythrophylic and associated proteins during acute infection of splenectomized and intact calves.
Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen.
Bacterial metastasis: the host plasminogen system in bacterial invasion.
Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Binding of plasminogen to Escherichia coli adhesion proteins.
Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Contribution of plasminogen activation towards the pathogenic potential of oral streptococci.
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice.
Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.
Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury.
Effect of ions and inhibitors on the catalytic activity and structural stability of S. aureus enolase.
Elevation of tear fluid plasmin in corneal disease.
Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells.
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Expression, genetic localization and phylogenic analysis of NAPlr in piscine Streptococcus dysgalactiae subspecies dysgalactiae isolates and their patterns of adherence.
Fibrin and fibrinolysis in infection and host defense.
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Herpesviruses enhance fibrin clot lysis.
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Influence of plasma protease activation on electroimmunoassay and nephelometry of plasma fibronectin in sepsis.
Interaction of Trypanosoma evansi with the plasminogen-plasmin system.
Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta).
Intracellular/surface moonlighting proteins that aid in the attachment of gut microbiota to the host.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients.
Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate.
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Molecular cloning and expression analysis of coagulation factor VIII and plasminogen involved in immune response to GCRV, and immunity activity comparison of grass carp Ctenopharyngodon idella with different viral resistance.
Molecular mechanisms underlying group A streptococcal pathogenesis.
Moonlighting glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells.
Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Nonfibrinolytic functions of plasminogen.
Oligosaccharide processing in the expression of human plasminogen cDNA by lepidopteran insect (Spodoptera frugiperda) cells.
Parasitism in optima forma: Exploiting the host fibrinolytic system for invasion.
Plasmin activity in the porcine airways is enhanced during experimental infection with Mycoplasma hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by vaccination.
Plasmin in Parasitic Chronic Infections: Friend or Foe?
Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing.
Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.
Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice.
Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments.
Production of outer membrane vesicles by the plague pathogen Yersinia pestis.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality.
Role of plasminogen in propagation of scrapie.
Role of secreted glyceraldehyde-3-phosphate dehydrogenase in the infection mechanism of enterohemorrhagic and enteropathogenic Escherichia coli: interaction of the extracellular enzyme with human plasminogen and fibrinogen.
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Secretion of the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase by the LEE-encoded type III secretion system in enteropathogenic Escherichia coli.
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis.
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms.
Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation.
Structural diversity of streptokinase and activation of human plasminogen.
Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen.
Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime.
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke.
The Bfp60 surface adhesin is an extracellular matrix and plasminogen protein interacting in Bacteroides fragilis.
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells.
The interaction between pathogens and the host coagulation system.
The interaction of Streptococcus dysgalactiae with plasmin and plasminogen.
The novel Leptospira interrogans protein Lsa32 is expressed during infection and binds laminin and plasminogen.
The novel leptospiral surface adhesin, Lsa20, binds laminin, human plasminogen and is probably expressed during infection.
The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.
The plasminogen activation system in periodontal tissue (Review).
The procoagulant envelope virus surface: contribution to enhanced infection.
The recombinant LIC10508 is a plasma fibronectin, plasminogen, fibrinogen and C4BP-binding protein of Leptospira interrogans.
The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase.
Tranexamic acid modulates the immune response and reduces postsurgical infection rates.
Trigger for group A streptococcal M1T1 invasive disease.
Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice.
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
[Enolase and parasitic infection].
[Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin]
[Hemostasis in patients with acute leukemia treated with high doses of cytosine-arabinoside: the effect of chemotherapy and infectious complications on hemostasis]
[The results of the measured oral infection of white mice with strains of the causative agent of plague differing in their plasmid profile]
Infertility
Possible role of the plasminogen activation system in human subfertility.
Tissue-type plasminogen activator level is decreased in human seminal plasma with abnormal liquefaction.
[Consequences for labile blood products of leukocyte depletion by whole blood filtration using the Leucoflex LST1 in-line filter. Evaluation of the Leucoflex LST1 filter]
Infertility, Female
[Serum plasminogen levels and timing of ovulation]
Inflammatory Bowel Diseases
Coagulation parameters in inflammatory bowel disease.
D-dimer tests detect both plasmin and neutrophil elastase derived split products.
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.
Influenza in Birds
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Influenza, Human
Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin.
Assays for functional binding of plasminogen to viral proteins.
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.
Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Proteolytic activation of the 1918 influenza virus hemagglutinin.
Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen.
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
[Role of neuraminidase in pathogenesis of influenza]
Insulin Resistance
Adiponectin levels may help assess the clinical repercussions of obesity irrespective of body mass index.
Cardiovascular issues in hypogonadism and testosterone therapy.
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Differential gene expression between visceral and subcutaneous fat depots.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women.
[Adipocitokines, adipose tissue and its relationship with immune system cells]
Intestinal Neoplasms
[Clinical study of hemostatic molecular markers expression in patients with cancer.]
Intestinal Obstruction
[Intraperitoneal administration of a solution of fibrinolysin, hydrocortisone and novocaine and its effect on blood coagulability in acute adhesive intestinal obstruction]
Intestinal Volvulus
Molecular cloning of an alpha-enolase from the human filarial parasite Onchocerca volvulus that binds human plasminogen.
Intra-Abdominal Hypertension
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Intracranial Aneurysm
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice.
Intracranial Embolism
Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
[Cerebral embolism after electric depolarization of a patient with cardiac fibrillation treated with fibrinolysin]
Intracranial Hemorrhages
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Gender differences in the outcome of interventional cardiac procedures.
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system.
Outcomes in acute ischemic strokes presenting with disabling neurologic deficits without intracranial vascular occlusion.
Pharmacologic and clinical characteristics of thrombolytic agents.
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury.
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stro